To study the influence of serum-free B27 supplemented culture medium on corneal epithelial cells from limbal explants.
Human limbal tissues obtained from cadaveric donor eyes were used in this study. The morphological characteristics of cultivated epithelial cells were analyzed by phase contrast microscopy. Growth kinetics, bromodeoxyuridine (BrdU) labeling cell proliferation assay, and reverse transcriptase PCR (RT–PCR) for limbus and corneal markers were studied in serum-dependent and serum-free B27 supplemented corneal epithelial culture. The signaling pathway genes were analyzed by RT2 qPCR profiler array.
The corneal epithelial cells morphology and mRNA expression of markers were similar in both the serum-dependent and serum-free B27 supplemented culture. The growth and proliferation of the serum-free B27 supplemented culture was significantly higher than that of the serum-dependent culture. The wnt, hedgehog, survival, NFkB, Jak-Stat, and calcium protein kinase C pathways were highly expressed in the serum-free B27 supplemented corneal epithelial culture.
Most signaling pathway genes are upfolded by B27 supplementation in the corneal epithelial cell culture; it could be an efficient replacement for serum.
Limbal deficiency or loss of corneal stem cells is associated with ocular surface disease, which is otherwise known as limbal stem cell deficiency (LSCD). The management of the ocular surface using cultured corneal epithelial cells on a human amniotic membrane is preferred. The ex vivo expansion of limbus culture requires unknown factors, such as fetal bovine serum (FBS), autologous serum, feeder layers or bovine pituitary extracts (BPE), as growth factors for the growth of corneal epithelial cells. The usage of these substances raises concern about infection with recognized or unknown-agents [
B27 was originally optimized for culture of hippocampal neurons and used for the growth of neurons from embryonic rat striatum, the substantia nigra, the subiculum, the cerebral cortex, the postnatal dentate granule, the cerebellum, and the dentate gyrus in a serum-free condition [
Therefore, we have tried to avoid serum, feeder layers, and/or bovine pituitary extract (BPE) in the culturing of corneal limbal stem cells. Instead, we used a serum-free medium supplemented with the growth factor B27 and analyzed the genes involved in the signal transduction pathway by RT2 qPCR profiler array.
Human cadaveric eyeballs were obtained from the C.U. Shah eye bank of the Medical Research Foundation, Sankara Nethralaya, Chennai, India with the consent of the donor or donor family to be used for medical research in accordance with the principles outlined in the Declaration of Helsinki. In this study, we collected limbus tissues from donors (n=12) aged between 67and 82 years. Corneal limbal tissues of 2 mm in length were collected in Dulbecco’s Modified Eagle Medium (DMEM; Sigma Chemicals, St. Louis, MO) with antibiotics (Sigma Chemicals) and transported to the cell biology laboratory for further processing. The donor blood samples were screened for human immunodeficiency virus (HIV) type 1 and 2, hepatitis B virus (HBV), hepatitis C virus (HCV), and
The collected limbal tissue was washed thrice with Hanks balanced salt solution buffer (Sigma Chemicals). After careful removal of excessive sclera and conjunctiva, the tissue was cut into multiple bits using a sharp, sterile Bard-Parker blade (Niraj Industries, Faridabad, India). The tissue bits were placed on a culture plate (BD biosciences, San Jose, CA) using a sterile needle. The plate was incubated at 37 °C and 5% CO2 for 5 min for adhesion. The explants were covered with culture medium containing equal volumes of DMEM and F12 (Sigma Chemicals) containing 5 ng/ml of epidermal growth factor (EGF), 5 μg/ml of insulin, 5 μg/ml of transferrin, 5 ng/ml of sodium selenite, 0.5 mg/ml of hydrocortisone, and 1% antibiotic solution (Sigma Chemicals). Ten percent FBS (Sigma Chemicals) was added to five cultures (serum-dependent culture; n=5) and 1% B27 supplement (Sigma Chemicals) was added to the other five cultures (serum-free B27 supplemented culture; n=5). The control samples were cultured without serum and/or any other supplement replacing serum (control culture; n=2). The plates were incubated at 37 °C and 5% CO2 with 95% humidity. The medium was changed once every two days and growth was monitored daily with an inverted phase contrast microscope (Nikon, Tokyo, Japan). Confluent cells were harvested for further molecular characterization.
The outgrowth of all the cultures was photographed every second day; images were transferred to a computer and analyzed using quantity G area measurement software [
Cell proliferation was assessed by measuring 5-bromo-2-deoxyuridine (Qiagen, Santa Clara, CA) incorporation during DNA synthesis in proliferating cells. The detection of BrdU was performed according to the manufacturer’s instruction and chased for 1–21 days. The BrdU labeling indices were assessed by counting the nuclei through a microscope using a 40× objective. The labeling index was expressed as the number of positively labeled nuclei/total number of nuclei×100%.
The cultures were trypsinised on the 8th day (limbal stem cells) and the 21st day (differentiated corneal cells) from both serum-dependent and serum-free B27 supplemented cultures. The RNA was isolated using the Rneasy (Qiagen) kit according to the manufacturer’s instructions. For RT2 qPCR array, the integrity and purity of the RNA were verified using a bioanalyzer chip (Agilent Technologies Genotypic, Bangalore, India).
The expression of marker genes (Bangalore Genei, Bangalore, India;
|
|
|
|
|
|---|---|---|---|
|
|
FP:AGTTCCATGGCACTGGCCATA |
62 |
379 |
| |
RP:TCAGGTAGGCAATTGTGAAGG |
|
|
|
|
FP:CAGACTCAATTTAGTGAG |
54 |
440 |
| |
RP:AGCTCATGGTTGGGGCAC |
|
|
| Connexin 43 |
FP:CCTTCTTGCTGATCCAGTGGTAC |
66 |
154 |
| |
RP:ACCAAGGACACCACCAGCAT |
|
|
| Keratin3 |
FP: GGCAGAGATCGAGGGTGTC |
64 |
145 |
| |
RP: GTCATCCTTCGCCTGCTGTAG |
|
|
| Keratin12 |
FP:CATGAAGAAGAACCACGAGGATG |
63 |
150 |
| |
RP:TCTGCTCAGCGATGGTTTCA |
|
|
|
|
FP:GCCAAGGTCATCCATGACAAC |
63 |
498 |
| RP:GTCCACCACCCTGTTGCTGTA |
The RT2 qPCR profiler Human Signal Transduction Pathway array (catalog number PAHS-014; SABiosciences, Frederick, MD), representing 84 genes involved in signal transduction pathways, plus five housekeeping genes and three controls, was used to analyze the effect of serum on signaling-related gene expression in human limbal and corneal epithelial cells. The total RNA was isolated from the limbus and corneal cells (serum-dependent and serum-free B27 supplemented culture) using the Rneasy Mini Kit (Qiagen). cDNA was generated from 1 µg total RNA using the RT2 qPCR Array First Strand Kit in accordance with the manual. The template was combined with RT2 SYBR Green/Fluorescein PCR master mix. Equal amounts of this mixture (25 μl) were added to each well of the RT2 qPCR profiler plate containing the predispensed gene-specific primer sets, and the reaction was performed using a sequence detector (ABI 7500; Applied Biosystems, LabIndia, Chennai, India) according to the manufacturer’s protocols. Data analysis was based on the ∆∆Ct method with the aid of an Excel (Microsoft Excel; Microsoft, Redmond, WA) spreadsheet containing algorithms provided by the manufacturer. The expression levels of the mRNA of each gene were normalized using the expression of the housekeeping gene
All experiments were performed in triplicate. The summary data were reported as the mean±standard deviation (SD), and were compiled and analyzed on a computer (Microsoft Excel; Microsoft). The mean and SD were calculated for each group using the Student’s
Under microscopic observation, we noted epithelial migration from limbal explants at the end of 48 h in both serum-dependent and serum-free B27 supplemented cultures (
Epithelial cell migration from limbal explants. Epithelial cell migration from limbal explants in serum-free B27 supplemented at the end of 48 h (
The cells cultured in serum-free B27 supplemented medium showed significantly higher growth after 12 days (
Growth kinetics of corneal epithelial cultures plotted with area of growth in mm2 (x-axis), against serum-free B27 supplemented and serum-dependent cultures (y-axis).
The labeling index was high in serum-free B27 supplemented culture when compared to serum-dependent culture after 24 h. The cultures were reviewed continuously for 7, 14, and 21 days and the labeling indices were 50±7.76, 42±2.24, 20±2.0, and 12±0.2%, respectively, in serum-free B27 supplemented culture. Similarly, in the serum-dependent culture, the labeling indices were 48±3.2, 35±0.33, 17±1.7, and 9±1.1% for 7, 14, and 21 days, respectively (
Cell proliferation index plotted with BrdU labeling indices (x-axis), against serum-free B27 supplemented and serum-dependent cultures (y-axis).
Semiquantitative RT–PCR results showed similar expressions (
|
|
|
|
|---|---|---|
| ABCG2 |
- |
- |
| P63 |
+ |
+ |
| Connexin 43 |
+ |
+ |
| Keratin 3 |
+ |
+ |
| Keratin 12 | + | + |
RT–PCR for mRNA expression of putative limbal/corneal stem cell markers. Lane 1: Negative control; Lane 2: Positive control; Lane 3: serum-free B27 supplemented corneal cells; Lane 4: serum-dependent corneal cells; Lane 5: 100 bp DNA ladder.
The array experiment was performed in duplicate. A simple comparison was performed on data to assess the gene expression of a serum-free B27 supplemented culture in relation a serum-dependent culture as a control for limbal stem cells and differentiated corneal epithelial cells (
|
|
|
|
|
|
|---|---|---|---|---|
|
|
||||
| EGR1 |
12.06 |
1.16 |
Early growth response 1 |
AT225/G0S30 |
| FOS |
67.78 |
1.6 |
V-fos FBJ murine osteosarcoma viral oncogene homolog |
AP-1/C-FOS |
| JUN |
8.51 |
1.64 |
Jun oncogene |
AP-1/AP1 |
|
|
||||
| CCND1 |
4.28 |
−1.72 |
Cyclin D1 |
BCL1/D11S287E |
| JUN |
8.51 |
1.64 |
Jun oncogene |
AP-1/AP1 |
| LEF1 |
12.06 |
1.13 |
Lymphoid enhancer-binding factor 1 |
DKFZp586H0919/TCF1ALPHA |
| MYC |
4.28 |
−3.56 |
V-myc myelocytomatosis viral oncogene homolog (avian) |
MRTL/bHLHe39 |
| PPARG |
2.14 |
−1.33 |
Peroxisome proliferator-activated receptor gamma |
CIMT1/NR1C3 |
| TCF7 |
12.06 |
1.13 |
Transcription factor 7 (T-cell specific, HMG-box) |
TCF-1 |
| VEGFA |
1.07 |
−1.74 |
Vascular endothelial growth factor A |
MVCD1/VEGF |
| WISP1 |
11.65 |
1.13 |
WNT1 inducible signaling pathway protein 1 |
CCN4/WISP1c |
|
|
||||
| BMP2 |
8.52 |
−3.57 |
Bone morphogenetic protein 2 |
BMP2A |
| BMP4 |
4.32 |
−2.46 |
Bone morphogenetic protein 4 |
BMP2B/BMP2B1 |
| EN1 |
11.76 |
1.13 |
Engrailed homeobox 1 |
Engrailed 1 |
| FOXA2 |
12.06 |
1.13 |
Forkhead box A2 |
HNF3B/TCF3B |
| PTCH1 |
2.01 |
−2.46 |
Patched homolog 1 (Drosophila) |
BCNS/HPE7 |
| WNT1 |
12.06 |
1.13 |
Wingless-type MMTV integration site family, member 1 |
INT1 |
| WNT2 |
12.06 |
1.17 |
Wingless-type MMTV integration site family member 2 |
INT1L1/IRP |
|
|
||||
| CDKN1A |
3.00 |
−2.47 |
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
CAP20/CDKN1 |
| CDKN1B |
5.99 |
1.65 |
Cyclin-dependent kinase inhibitor 1B (p27, Kip1) |
CDKN4/KIP1 |
| CDKN2A |
−1.34 |
−6.95 |
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) |
ARF/CDK4I |
| CDKN2B |
2.12 |
−1.75 |
Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
CDK4I/INK4B |
|
|
||||
|
|
||||
| BCL2 |
12.06 |
1.13 |
B-cell CLL/lymphoma 2 |
Bcl-2 |
| CCND1 |
4.28 |
−1.72 |
Cyclin D1 |
BCL1/D11S287E |
| JUN |
8.51 |
1.64 |
Jun oncogene |
AP-1/AP1 |
| MYC |
4.28 |
−3.56 |
V-myc myelocytomatosis viral oncogene homolog (avian) |
MRTL/bHLHe39 |
|
|
||||
| BCL2 |
12.06 |
1.13 |
B-cell CLL/lymphoma 2 |
Bcl-2 |
| BCL2L1 |
6.03 |
−7.04 |
BCL2-like 1 |
BCL-XL/S |
|
|
||||
| BCL2A1 |
1.50 |
2.33 |
BCL2-related protein A1 |
ACC-1/ACC-2 |
| BIRC2 |
2.13 |
3.24 |
Baculoviral IAP repeat-containing 2 |
API1/HIAP2 |
| BIRC3 |
1.06 |
−2.48 |
Baculoviral IAP repeat-containing 3 |
AIP1/API2 |
| NAIP (BIRC1) |
2.13 |
1.14 |
NLR family, apoptosis inhibitory protein |
BIRC1/NLRB1 |
| TERT |
12.06 |
1.13 |
Telomerase reverse transcriptase |
EST2/TCS1 |
|
|
||||
| BAX |
3.01 |
−14.1 |
BCL2-associated X protein |
BCL2L4 |
| CDKN1A |
3.00 |
−2.47 |
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
CAP20/CDKN1 |
| Fas |
−1.33 |
−1.25 |
Fas (TNF receptor superfamily, member 6) |
ALPS1A/APO-1 |
| GADD45A |
5.99 |
2.26 |
Growth arrest and DNA-damage-inducible, alpha |
DDIT1/GADD45 |
| IGFBP3 |
−14.95 |
−40 |
Insulin-like growth factor binding protein 3 |
BP-53/IBP3 |
| MDM2 |
1.06 |
−4.93 |
Mdm2 p53 binding protein homolog (mouse) |
HDMX/hdm2 |
| TP5313 |
4.28 |
−1.22 |
Tumor protein p53 inducible protein 3 |
PIG3 |
|
|
||||
| ATF2 |
3.01 |
−2.48 |
Activating transcription factor 2 |
CRE-BP1/CREB2 |
| FOS |
67.78 |
1.6 |
V-fos FBJ murine osteosarcoma viral oncogene homolog |
AP-1/C-FOS |
| HSF1 (tcf5) |
4.25 |
1.15 |
Heat shock transcription factor 1 |
HSTF1 |
| HSPB1 (hsp27) |
4.27 |
−1.25 |
Heat shock 27 kDa protein 1 |
CMT2F/DKFZp586P1322 |
| HSPCA (hsp90) |
1.50 |
−3.48 |
Heat shock protein 90 kDa alpha (cytosolic), class A member 2 |
HSP90ALPHA/HSPCA |
| MYC |
4.28 |
−3.56 |
V-myc myelocytomatosis viral oncogene homolog (avian) |
MRTL/bHLHe39 |
| TP53 |
1.07 |
−1.75 |
Tumor protein p53 |
LFS1/TRP53 |
|
|
||||
| IKBKB |
2.11 |
−2.53 |
Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
IKK-beta/IKK2 |
| IL1A |
8.48 |
3.27 |
Interleukin 1, alpha |
IL-1A/IL1 |
| IL2 |
11.72 |
1.17 |
Interleukin 2 |
IL-2/TCGF |
| IL8 |
1.53 |
−9.92 |
Interleukin 8 |
CXCL8/GCP-1 |
| LTA (TNF beta) |
11.75 |
1.13 |
Lymphotoxin alpha (TNF superfamily, member 1) |
LT/TNFB |
| NOS2A (iNOS) |
1.42 |
−3.52 |
Nitric oxide synthase 2, inducible |
HEP-NOS/INOS |
| PECAM1 |
8.03 |
1.09 |
Platelet/endothelial cell adhesion molecule |
CD31/PECAM-1 |
| TANK |
5.70 |
−3.63 |
TRAF family member-associated NFKB activator |
I-TRAF/TRAF2 |
| TNF |
7.99 |
−1.75 |
Tumor necrosis factor (TNF superfamily, member 2) |
DIF/TNF-alpha |
| VCAM1 |
12.06 |
1.13 |
Vascular cell adhesion molecule 1 |
CD106/DKFZp779 G2333 |
|
|
||||
| CD5 |
11.65 |
1.13 |
CD5 molecule |
LEU1/T1 |
| FASLG (TNFSF6) |
11.69 |
1.16 |
Fas ligand (TNF superfamily, member 6) |
APT1LG1/CD178 |
| IL2 |
11.72 |
1.17 |
Interleukin 2 |
IL-2/TCGF |
|
|
||||
| CYP19A1 |
11.27 |
1.13 |
Cytochrome P450, family 19, subfamily A, polypeptide 1 |
ARO/ARO1 |
| EGR1 |
12.06 |
1.16 |
Early growth response 1 |
AT225/G0S30 |
| FOS |
67.78 |
1.6 |
V-fos FBJ murine osteosarcoma viral oncogene homolog |
AP-1/C-FOS |
|
|
||||
| CXCL9 |
11.14 |
1.13 |
Chemokine (C-X-C motif) ligand 9 |
CMK/Humig |
| IL4 |
11.33 |
1.13 |
Interleukin 4 |
BCGF-1/BCGF1 |
| IL4R |
1.51 |
−3.52 |
Interleukin 4 receptor |
CD124/IL4RA |
| MMP10 |
3.02 |
−1.76 |
Matrix metallopeptidase 10 (stromelysin 2) |
SL-2/STMY2 |
| NOS2A (iNOS) |
1.42 |
−3.52 |
Nitric oxide synthase 2, inducible |
HEP-NOS/INOS |
|
|
||||
| BCL2 |
12.06 |
1.13 |
B-cell CLL/lymphoma 2 |
Bcl-2 |
| BRCA1 |
8.50 |
1.1 |
Breast cancer 1, early onset |
BRCAI/BRCC1 |
| GREB1 |
11.72 |
1.16 |
GREB1 protein |
KIAA0575 |
| NRIP1 |
−1.32 |
−3.51 |
Nuclear receptor interacting protein 1 |
RIP140 |
|
|
||||
| CDK2 |
8.55 |
−1.75 |
Cyclin-dependent kinase 2 |
p33(CDK2) |
| CDKN1A |
3.00 |
−2.47 |
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) |
CAP20/CDKN1 |
| KLK2 |
11.41 |
1.16 |
Kallikrein-related peptidase 2 |
KLK2A2/hK2 |
| TMEPAI |
−1.87 |
−1.74 |
Prostate transmembrane protein, androgen induced 1 |
STAG1/TMEPAI |
|
|
||||
| CSF2 |
11.42 |
−1.84 |
Colony stimulating factor 2 (granulocyte-macrophage) |
GMCSF |
| FOS |
67.78 |
1.6 |
V-fos FBJ murine osteosarcoma viral oncogene homolog |
AP-1/C-FOS |
| IL2 |
11.72 |
1.17 |
Interleukin 2 |
IL-2/TCGF |
| JUN |
8.51 |
1.64 |
Jun oncogene |
AP-1/AP1 |
| MYC |
4.28 |
−3.56 |
V-myc myelocytomatosis viral oncogene homolog (avian) |
MRTL/bHLHe39 |
| ODC1 |
8.54 |
1.65 |
Ornithine decarboxylase 1 |
ODC |
| PRKCA |
5.62 |
1.13 |
Protein kinase C, alpha |
AAG6/PKC-alpha |
| PRKCE |
2.92 |
−2.48 |
Protein kinase C, epsilon |
PKCE/nPKC-epsilon |
| TFRC |
−1.30 |
−1.74 |
Transferrin receptor (p90, CD71) |
CD71/TFR |
|
|
||||
| BCL2 |
12.06 |
1.13 |
B-cell CLL/lymphoma 2 |
Bcl-2 |
| EGR1 |
12.06 |
1.16 |
Early growth response 1 |
AT225/G0S30 |
| FOS |
67.78 |
1.6 |
V-fos FBJ murine osteosarcoma viral oncogene homolog |
AP-1/C-FOS |
| ICAM1 |
−2.68 |
−20.07 |
Intercellular adhesion molecule 1 |
BB2/CD54 |
| JUN |
8.51 |
1.64 |
Jun oncogene |
AP-1/AP1 |
| NOS2A |
1.42 |
−3.52 |
Nitric oxide synthase 2, inducible |
HEP-NOS/INOS |
| PTGS2 |
23.98 |
4.57 |
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
COX-2/COX2 |
| VCAM1 |
12.06 |
1.13 |
Vascular cell adhesion molecule 1 |
CD106/DKFZp779G2333 |
|
|
||||
| CEBPB |
2.90 |
3.3 |
CCAAT/enhancer binding protein (C/EBP), beta |
C/EBP-beta |
| FASN |
4.26 |
1.14 |
Fatty acid synthase |
FAS/OA-519 |
| GYS1 |
3.03 |
3.29 |
Glycogen synthase 1 (muscle) |
GSY/GYS |
| HK2 |
2.99 |
1.69 |
Hexokinase 2 |
DKFZp686M1669/HKII |
| LEP |
12.06 |
1.13 |
Leptin |
OB/OBS |
|
|
||||
| CCL2 |
8.79 |
1.13 |
Chemokine (C-C motif) ligand 2 |
GDCF-2/HC11 |
| CSF2 |
11.42 |
−1.84 |
Colony stimulating factor 2 (granulocyte-macrophage) |
GMCSF |
| SELE |
11.70 |
1.13 |
Selectin E |
CD62E/ELAM |
| SELPLG |
12.06 |
1.13 |
Selectin P ligand |
CD162/CLA |
| VCAM1 |
12.06 |
1.13 |
Vascular cell adhesion molecule 1 |
CD106/DKFZp779 G2333 |
|
|
||||
| EN1 |
11.76 |
1.13 |
Engrailed homeobox1 |
Engrailed 1 |
| HOXA1 |
12.06 |
1.13 |
Homeobox A1 |
BSAS/HOX1 |
| RBP1 (CRBP1) | 1.06 | −1.74 | Retinol binding protein 1, cellular | CRABP-I/CRBP |
Six Pathways with relatively high expressions representing corresponding genes by RT2 qPCR profiler array of serum-free B27 supplemented limbus and corneal epithelial cells. Serum-dependent cultured limbus and corneal epithelial cells are the respective controls.
We have demonstrated the use of serum-free B27 supplemented medium for the growth of corneal epithelial cells. This serum-free medium supported the proliferation and viability of the cells. The cells expressed presumed limbal stem cell association markers and the cornea phenotype, suggesting that the serum-free B27 supplemented medium retained the stemness of cultured cells. The confluent culture was collected and RNA was isolated to analyze the signaling pathway genes involved in both serum-dependent and serum-free B27 supplemented cultures.
The signal transduction pathway genes involved in the growth of corneal epithelial cells help to determine their role in both serum-dependent and serum-free B27 supplemented corneal epithelial cultures. Among the 17 pathways, six pathways involved in the serum-free B27 supplemented culture were discussed, along with their roles in serum-free limbal stem cell and differentiated corneal epithelial cell cultures.
In the serum-free condition of the corneal epithelial cells, the activation of wnt pathway plays a vital role by activating genes like
In conclusion, the B27 supplement activated more signaling pathway genes, helping to provide a higher cell number, good capacity for proliferation, better quality, and more functional pieces of engineered corneal equivalents without the support of serum, a feeder layer, and/or BPE.
The authors would like to thank the Indian Council of Medical Research (Grant No: 80/7/2003-BMS) for financial support.